{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:04:09Z","timestamp":1789790649963,"version":"4.0.1"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,9,15]]},"DOI":"10.2169\/internalmedicine.6726-25","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T22:10:55Z","timestamp":1770675055000},"page":"2444-2448","source":"Crossref","is-referenced-by-count":0,"title":["Diverticular Perforation with Normal C-reactive Protein in a Patient with Neuromyelitis Optica Spectrum Disorder Receiving Satralizumab"],"prefix":"10.2169","volume":"65","author":[{"given":"Miharu","family":"Kitazawa","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Osugi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Hayano","sequence":"additional","affiliation":[{"name":"Department of Neurology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Yokoe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyonaka Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Matsumoto K, Nishida T, Nakamatsu D, et al. An increase in aspartate aminotransferase can predict worsening disease severity in Japanese patients with COVID-19. Clin Pract 14: 1601-1614, 2024.","DOI":"10.3390\/clinpract14040129"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol 68: 2612-2617, 2016.","DOI":"10.1002\/art.39761"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jovani M, Ma W, Staller K, et al. Frequency of bowel movements and risk of diverticulitis. Clin Gastroenterol Hepatol 20: 325-333, e5, 2022.","DOI":"10.1016\/j.cgh.2021.01.003"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Soma K, Nakamatsu D, Nishida T, et al. Efficacy and safety of a strategy for reviewing intravenous antibiotics for hospitalized Japanese patients with uncomplicated diverticulitis: a single-center observational study. Intern Med 61: 3475-3482, 2022.","DOI":"10.2169\/internalmedicine.9361-22"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6: a016295, 2014.","DOI":"10.1101\/cshperspect.a016295"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Strangfeld A, Richter A, Siegmund B, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis 76: 504-510, 2017.","DOI":"10.1136\/annrheumdis-2016-209773"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Barbulescu A, Delcoigne B, Askling J, Frisell T. Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study. RMD Open 6: e001201, 2020.","DOI":"10.1136\/rmdopen-2020-001201"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Rempenault C, Lukas C, Combe B, et al. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology (Oxford) 61: 953-962, 2022.","DOI":"10.1093\/rheumatology\/keab438"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gout T, Ostor AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 30: 1471-1474, 2011.","DOI":"10.1007\/s10067-011-1827-x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rojo M, Cano-Valderrama O, Picazo S, et al. Gastrointestinal perforation after treatment with tocilizumab: an unexpected consequence of COVID-19 pandemic. Am Surg 86: 565-566, 2020.","DOI":"10.1177\/0003134820926481"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gonz\u00e1lvez Guardiola P, D\u00edez Ares J\u00c1, Peris Tom\u00e1s N, Sebasti\u00e1n Tom\u00e1s JC, Navarro Mart\u00ednez S. Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case. Cir Esp (Engl Ed) 99: 156-157, 2021 (in Spanish).","DOI":"10.1016\/j.cireng.2021.01.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kuhn KA, Manieri NA, Liu TC, Stappenbeck TS. IL-6 stimulates intestinal epithelial proliferation and repair after injury. PLoS One 9: e114195, 2014.","DOI":"10.1371\/journal.pone.0114195"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Jin X, Zimmers TA, Zhang Z, Pierce RH, Koniaris LG. Interleukin-6 is an important in vivo inhibitor of intestinal epithelial cell death in mice. Gut 59: 186-196, 2010.","DOI":"10.1136\/gut.2008.151175"},{"key":"14","unstructured":"14. Pharmaceuticals and Medical Devices Agency (PMDA). Review report: satralizumab (Enspryng) [Internet]. [cited 2025 Aug 11]. Available from: https:\/\/www.pmda.go.jp\/files\/000244464.pdf"},{"key":"15","unstructured":"15. U.S. Food and Drug Administration (FDA). Multidiscipline review: satralizumab (Enspryng) [Internet]. [cited 2025 Aug 11]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/761149Orig1s000SumR.pdf"},{"key":"16","unstructured":"16. Swissmedic. Satralizumab (Enspryng) Risk Management Plan Summary [Internet]. [cited 2025 Aug 11]. Available from: https:\/\/www.swissmedic.ch\/dam\/swissmedic\/de\/dokumente\/marktueberwachung\/rmp\/satralizumab_enspryng-rmp-summary.pdf.download.pdf\/satralizumab_Enspryng_rmpsummary.pdf"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yanagawa Y, Hirano Y, Kato H, Iba T. The absence of typical pneumonia symptoms in a patient with rheumatoid arthritis during tocilizumab and steroid treatment. BMJ Case Rep 2012: bcr0220125835, 2012.","DOI":"10.1136\/bcr.02.2012.5835"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bari SF, Khan A, Lawson T. C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab. BMJ Case Rep 2013: bcr2013010423, 2013.","DOI":"10.1136\/bcr-2013-010423"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Heo YA. Satralizumab: first approval. Drugs 80: 1477-1482, 2020.","DOI":"10.1007\/s40265-020-01380-2"},{"key":"20","unstructured":"20. Kumpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management. J Neurol 271: 141-176, 2024."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol 93: 1053-1068, 2023.","DOI":"10.1002\/ana.26626"},{"key":"22","unstructured":"22. Japanese Society for Hematology. [Paroxysmal nocturnal hemoglobinuria: clinical practice guide (2022 revised edition)] [Internet]. Available from: https:\/\/zoketsushogaihan.umin.jp\/file\/2022\/Paroxysmal_nocturnal_hemoglobinuria2022.pdf (in Japanese)"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/18\/65_6726-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:31:15Z","timestamp":1789788675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/18\/65_6726-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":22,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6726-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"6726-25"}}